Search results
Results from the WOW.Com Content Network
The following are settlements reached with US authorities against pharmaceutical companies to resolve allegations of "off-label" promotion of drugs. Under the Federal Food, Drug, and Cosmetic Act, it is illegal for pharmaceutical companies to promote their products for uses not approved by the Food and Drug Administration (FDA), and corporations that market drugs for off-label indications may ...
In the Washington, D.C. metropolitan area, plans open to all federal employees and annuitants include 10 fee-for-service and PPO plans, seven HMOs, and eight high-deductible and consumer-driven plans. [4] In the FEHB program the federal government sets minimal standards that, if met by an insurance company, allows it to participate in the program.
Results after the first year of this program indicated that 62% of employees participated in at least one wellness activity, 51% exercising more often, 50% stating wellness programs as the most popular activity, 49% eating more fruits and vegetables, 27% were closer to a healthy weight, and 106 employees stopped smoking and 149 reduced tobacco use.
This new study is part of a larger clinical trial that previously showed that weekly tirzepatide injections resulted in weight loss of up to 22% in adults with overweight or obesity, helping ...
Clinical trials in the US are registered on clinicaltrials.gov. Clinicaltrials.gov is the largest clinical trials registry. Clinical trials conducted in the United States are required to be registered in the registry. Its registrations represent about 75% of what is available through the WHO portal (ICTRP).
For premium support please call: 800-290-4726 more ways to reach us
Under Medicare guidelines, hospice patients require a terminal diagnosis or markers of a life-threatening condition — such as severe weight loss or loss of mobility — indicating the person will likely die within six months or sooner. Maples did not have a terminal illness. Her diagnosis was “debility, unspecified,” according to her records.
The two clinical studies would examine ceftobiprole for the treatment of “Staphylococcus aureus bacteremia (bloodstream infections) and acute bacterial skin and skin structure infections.” [40] Basilea signed a contract with BARDA, which it entered into in 2016 for the clinical phase 3 development of the antibiotic. BARDA provided initial ...